Herpes zoster in immunocompromised patients: Incidence, timing, and risk factors - 21/08/11
WGET Research Group
Requests for reprints should be addressed to John H. Stone, MD, MPH, The Johns Hopkins Vasculitis Center, 5501 Hopkins Bayview Circle, 1B23, Baltimore, MD 21224.Abstract |
Purpose |
To evaluate the risk factors for herpes zoster as well as the incidence and timing of this complication in patients who were treated with immunosuppression because of active Wegener’s granulomatosis.
Subjects and methods |
We studied the 180 Wegener’s granulomatosis patients in the Wegener’s Granulomatosis Etanercept Trial (WGET). Herpes zoster events during WGET were documented prospectively. Follow-up questionnaires were employed to describe the location, treatment, and complication(s) of herpes zoster and its therapy. Univariate and multivariate analyses were performed to evaluate risk factors, including history of herpes zoster, for the occurrence of herpes zoster during the trial. All analyses were based on the time to first occurrence of herpes zoster.
Results |
Eighteen patients (10% of the WGET cohort) suffered a total of 19 herpes zoster episodes over a mean follow-up period of 27 months. The annual incidence of herpes zoster in the WGET cohort was 45 cases/1000 patient-years (95% confidence interval [CI]: 27, 70). The median time from enrollment to the occurrence of herpes zoster in the subgroup of patients with that complication was 16.5 months (± 9.4). Fifteen of the 19 herpes zoster events (79%) occurred between months 6 and 36, many months after the period of most intensive immunosuppression. In univariate analyses, history of serum creatinine ≥1.5 mg/dL before enrollment was associated with a relative risk (RR) of 3.0 (95% CI: 1.1, 7.8) for herpes zoster during WGET (P=.03). In multivariate analyses, serum creatinine ≥1.5 mg/dL was associated with an RR of 6.3 (95% CI: 2.0, 19.8; P=.002), and female sex with an RR of 4.6 (95% CI: 1.6, 13.2; P=.004).
Conclusion |
Renal dysfunction and female sex were consistently strong risk factors for herpes zoster events in this population. Contrary to expectation, most herpes zoster events did not occur during periods of most intensive immunosuppression. These data may inform studies of interventions designed to prevent herpes zoster in patients on treatment for immune-mediated diseases.
Le texte complet de cet article est disponible en PDF.Keywords : Herpes zoster, Incidence, Renal insufficiency, Immunosuppression, Wegener’s granulomatosis
Plan
| This study was supported by the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (Contract Number N01-AR-9-2240); The Food and Drug Administration/Office of Orphan Products (Grant Number FD-R-001652-01); General Clinical Research Center Grants M01-RRO-2719 (Johns Hopkins University School of Medicine), M01-RRO-00533 (Boston University), M01-RRO-0042 (The University of Michigan), and M01-RR-30 (Duke University) from the National Center for Research Resources/NIH; and Amgen Corporation, Thousand Oaks, Calif. |
Vol 118 - N° 12
P. 1416.e9-1416.e18 - décembre 2005 Retour au numéro
Article précédent
- The natural history of post-traumatic hypopituitarism: Implications for assessment and treatment
- Amar Agha, Jack Phillips, Patrick O’Kelly, William Tormey, Christopher J. Thompson
- Staphylococcus aureus bacteremia in patients with prosthetic devices: Costs and outcomes
- Vivian H. Chu, David R. Crosslin, Joelle Y. Friedman, Shelby D. Reed, Christopher H. Cabell, Robert I. Griffiths, Leah E. Masselink, Keith S. Kaye, G. Ralph Corey, L. Barth Reller, Martin E. Stryjewski, Kevin A. Schulman, Vance G. Fowler
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?